<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10647">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968355</url>
  </required_header>
  <id_info>
    <org_study_id>SDY-017266</org_study_id>
    <nct_id>NCT02968355</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the FilmArray® Global Fever (GF) Panel</brief_title>
  <official_title>Clinical Evaluation of the FilmArray® Global Fever (GF) Panel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioFire Defense LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>BioFire Defense LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical sensitivity and specificity of the FilmArray Global
      Fever (GF) Panel.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical sensitivity and specificity of the FilmArray Global Fever (GF) Panel</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Subjects/Specimens</arm_group_label>
    <description>Subjects/Specimens that meet the eligibility criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Observational study</description>
    <arm_group_label>Subjects/Specimens</arm_group_label>
    <other_name>FilmArray</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood specimen may be retained at the participating clinical sites for future use.
      Specimen nucleic acid may be retained at BioFire and participating clinical sites for future
      performance evaluations of the FilmArray.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with fever will be prospectively enrolled, and whole blood will be collected.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Whole blood in EDTA (prospectively collected via informed consent)

          -  Subject has a recorded or self-reported fever within the past two days.

          -  Subject has not previously been enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Phillips, Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>BioFire Defense LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Andjelic, Ph. D.</last_name>
    <phone>801-262-3592</phone>
    <phone_ext>1173</phone_ext>
    <email>Cynthia.Andjelic@BioFireDefense.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kenya Medical Research Unit</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Waitumbi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Armed Forces Research Institute of Medical Sciences</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damon Ellison</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 16, 2016</lastchanged_date>
  <firstreceived_date>November 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
